相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer.
V. Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
RNA Aptamers as Conformational Probes and Regulatory Agents for Plasminogen Activator Inhibitor-1
Jeppe B. Madsen et al.
BIOCHEMISTRY (2010)
Emerging biomarkers in breast cancer care
Rudolf Napieralski et al.
BIOMARKERS IN MEDICINE (2010)
Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
H. Taubert et al.
BRITISH JOURNAL OF CANCER (2010)
Analytical Validation of Protein-Based Multiplex Assays: A Workshop Report by the NCI-FDA Interagency Oncology Task Force on Molecular Diagnostics
Henry Rodriguez et al.
CLINICAL CHEMISTRY (2010)
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
Karin Mengele et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2010)
Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer
Parham Minoo et al.
HUMAN PATHOLOGY (2010)
HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients
Bent Ejlertsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib
D. Goldstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Classification of HER2 Receptor Status in Breast Cancer Tissues by MALDI Imaging Mass Spectrometry
Sandra Rauser et al.
JOURNAL OF PROTEOME RESEARCH (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Estrogen action: A historic perspective on the implications of considering alternative approaches
Elwood V. Jensen et al.
PHYSIOLOGY & BEHAVIOR (2010)
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA
David Sgier et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Cancer-related forecast biomarkers: a topic in focus of the Worldwide Innovative Network in Personalized Cancer Medicine (WIN)
Manfred Schmitt et al.
BIOANALYSIS (2010)
CXCL12-Mediated Induction of Plasminogen Activator Inhibitor-1 Expression in Human CXCR4 Positive Astroglioma Cells
Jae-Wook Oh et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression
H. Chen et al.
BRITISH JOURNAL OF CANCER (2009)
Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development
Daniel S. W. Tan et al.
CANCER JOURNAL (2009)
Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor
Yuqi Jing et al.
CANCER RESEARCH (2009)
The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Salvatore Ulisse et al.
CURRENT CANCER DRUG TARGETS (2009)
Multiplexed Fluorescence Imaging of Tumor Biomarkers in Gene Expression and Protein Levels for Personalized and Predictive Medicine
Mark Q. Smith et al.
CURRENT MOLECULAR MEDICINE (2009)
Translating the cancer genome into clinically useful tools and strategies
Federico Innocenti et al.
DISEASE MODELS & MECHANISMS (2009)
Predictive Value of the Differential Expression of the Urokinase Plasminogen Activation Axis in Radical Prostatectomy Patients
Amit Gupta et al.
EUROPEAN UROLOGY (2009)
Challenges in cancer research and multifaceted approaches for cancer biomarker quest
Jirina Martinkova et al.
FEBS LETTERS (2009)
Biochemical properties of plasminogen activator inhibitor-1
Daniel Miotto Dupont et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients
Li Wang et al.
GYNECOLOGIC ONCOLOGY (2009)
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo
Han Zhou et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
A Novel Mode of Intervention with Serine Protease Activity TARGETING ZYMOGEN ACTIVATION
Grant E. Blouse et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
uPA and PAI-1 in Rectal Cancer - Relationship to Radiotherapy and Clinical Outcome
Eva Angenete et al.
JOURNAL OF SURGICAL RESEARCH (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis
Maria Vincenza Carriero et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis
Maria Chiara Di Bernardo et al.
LUNG CANCER (2009)
MOLECULAR ORIGINS OF CANCER Gene-Expression Signatures in Breast Cancer
Christos Sotiriou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Antimetastatic Potential of PAI-1-Specific RNA Aptamers
Charlene M. Blake et al.
OLIGONUCLEOTIDES (2009)
Differential Prognostic Impact of uPA and PAI-1 in Colon and Rectal Cancer
Marcus Langenskiold et al.
TUMOR BIOLOGY (2009)
Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy
Masafumi Kumano et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
TIMP-1 as a tumor marker in breast cancer - An update
Sidse O. Wuertz et al.
ACTA ONCOLOGICA (2008)
Inhibition of plasminogen activator inhibitor-1 - Its mechanism and effectiveness on coagulation and fibrosis
Yuko Izuhara et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues
Paul N. Span et al.
BJU INTERNATIONAL (2008)
The Oral Serine Protease Inhibitor WX-671-First Experience in Patients with Advanced Head and Neck Carcinoma
Jens E. Meyer et al.
BREAST CARE (2008)
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects
Manfred Schmitt et al.
BREAST CARE (2008)
Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer
Lori J. Goldstein
BREAST CARE (2008)
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer
Inti Zlobec et al.
CANCER (2008)
The feasibility of uPA/uPAR-targeting strategies in cancer treatment
Shijie Sheng
CANCER BIOLOGY & THERAPY (2008)
Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor
Xian-wen Hu et al.
CANCER BIOLOGY & THERAPY (2008)
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Mitch Dowsett et al.
CLINICAL CANCER RESEARCH (2008)
A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
Michael J. Duffy et al.
CLINICAL CHEMISTRY (2008)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Catharine M. Sturgeon et al.
CLINICAL CHEMISTRY (2008)
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer
E. Steiner et al.
GYNECOLOGIC ONCOLOGY (2008)
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer
Sharad A. Ghamande et al.
GYNECOLOGIC ONCOLOGY (2008)
Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma
Takahiko Naka et al.
HUMAN PATHOLOGY (2008)
The plasminogen activator inhibitor paradox in cancer
Bernd R. Binder et al.
IMMUNOLOGY LETTERS (2008)
A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy
Qiming Sun et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Antibody-mediated Targeting of the Urokinase-type Plasminogen Activator Proteolytic Function Neutralizes Fibrinolysis in Vivo
Ida K. Lund et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state
Lisa Mathiasen et al.
MOLECULAR PHARMACOLOGY (2008)
Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma
Aiqun Xue et al.
PANCREAS (2008)
Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer
Ute WarneckeYEberz et al.
PANCREAS (2008)
S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood
Alain Rupin et al.
THROMBOSIS RESEARCH (2008)
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions
Mariusz Adam Goscinski et al.
ULTRASTRUCTURAL PATHOLOGY (2008)
Plasminogen activator system in oral squamous cell carcinoma
E. A. Baker et al.
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (2007)
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer
A. Foersti et al.
ANNALS OF ONCOLOGY (2007)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells
Elena P. Moiseeva et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity
Zonggao Shi et al.
BIOCHEMICAL JOURNAL (2007)
Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range
M. Meryet-Figuieres et al.
BIOCHIMIE (2007)
Opinion - Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
Christos Sotiriou et al.
NATURE REVIEWS CANCER (2007)
Interaction between cancer cells and stromnal fibroblasts is required for activation of the uPAR-uPA-NMP-2 cascade in pancreatic cancer metastasis
Yu He et al.
CLINICAL CANCER RESEARCH (2007)
Opinion - Shaping the future of biomarker research in breast cancer to ensure clinical relevance
M. Carolina Hinestrosa et al.
NATURE REVIEWS CANCER (2007)
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma
Lucienne Speleman et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2007)
Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice
Yunpeng Su et al.
CANCER RESEARCH (2007)
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis
Shahrokh F. Shariat et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, wxc-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases
S. D. Killeen et al.
BRITISH JOURNAL OF CANCER (2007)
Anthocyanidins inhibit migration of glioblastoma cells: Structure-activity relationship and involvement of the plasminolytic system
Sylvie Lamy et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis
Birgitte Vrou Offersen et al.
LUNG CANCER (2007)
PAI-1 - A potential therapeutic target in cancer
Peter A. Andreasen
CURRENT DRUG TARGETS (2007)
RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice
A. Salvi et al.
TUMOR BIOLOGY (2007)
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis
C. E. Leik et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Black rice anthocyanins inhibit cancer cells invasion via repressions of MMPs and u-PA expression
Pei-Ni Chen et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2006)
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition
Seung-Hyun Oh et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer
Paul J. Cozzi et al.
HUMAN PATHOLOGY (2006)
Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study
Gordana Horvatic Herceg et al.
WIENER KLINISCHE WOCHENSCHRIFT (2006)
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas
S. Ulisse et al.
EUROPEAN JOURNAL OF CANCER (2006)
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types
Ralph J. Abi-Habib et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer
T Sakakibara et al.
CANCER SCIENCE (2006)
Mulberry anthocyanins, cyanidin 3-rutinoside and cyanidin 3-glucoside, exhibited an inhibitory effect on the migration and invasion of a human lung cancer cell line
Pei-Ni Chen et al.
CANCER LETTERS (2006)
Urokinase system expression in gastric carcinoma - Prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens
BCM Beyer et al.
CANCER (2006)
Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma
A Salmaggi et al.
CANCER BIOLOGY & THERAPY (2006)
The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma:: Relation to prognosis
H Pappot et al.
LUNG CANCER (2006)
Antitumor efficacy of a urokinase activation-dependent anthrax toxin
B Rono et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells
HN Andrews et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer:: A phase I trial
A Berkenblit et al.
GYNECOLOGIC ONCOLOGY (2005)
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis
K Ohba et al.
JOURNAL OF UROLOGY (2005)
Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis
JK Hennan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
ACP Riddick et al.
BRITISH JOURNAL OF CANCER (2005)
Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer
SJ Shin et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2005)
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value
B Hundsdorfer et al.
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2005)
Gene expression profiling of breast cancer: A new tumor marker
LJ van't Veer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue
PA Usher et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Green tea polypheniols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells
V Slivova et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2005)
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma
T Sakakibara et al.
CLINICAL CANCER RESEARCH (2004)
UPA and uPAR in fibrinolysis, immunity and pathology
A Mondino et al.
TRENDS IN IMMUNOLOGY (2004)
Prognostic relevance of TGF-β1 and PAI-1 in cervical cancer
S Hazelbag et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation
H Kobayashi et al.
CLINICAL & EXPERIMENTAL METASTASIS (2004)
Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis
QD Chu et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2004)
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer
C Borgfeldt et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis
M Nagata et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Proteases in brain tumour progression
N Levicar et al.
ACTA NEUROCHIRURGICA (2003)
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder
SF Shariat et al.
UROLOGY (2003)
Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer
DQ Seetoo et al.
JOURNAL OF SURGICAL ONCOLOGY (2003)
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer
AS Schrohl et al.
MOLECULAR & CELLULAR PROTEOMICS (2003)
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis
A Loktionov et al.
CANCER LETTERS (2003)
Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer
T Kaneko et al.
CANCER SCIENCE (2003)
uPAR: A versatile signalling orchestrator
F Blasi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms
M Seddighzadeh et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas
S Papadopoulou et al.
TUMOR BIOLOGY (2002)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients
MP Look et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
PAI-1 and EGFR expression in adult glioma tumors: Toward a molecular prognostic classification
X Muracciole et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma
GS Hanekom et al.
CANCER DETECTION AND PREVENTION (2002)
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer
M Fredstorp-Lidebring et al.
EUROPEAN JOURNAL OF CANCER (2001)
The uPA/uPA receptor system as a target for tumor therapy
S Sperl et al.
DRUG NEWS & PERSPECTIVES (2001)
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages
NE Kushlinskii et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2001)
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms
ES Gershtein et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2001)
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
F Jänicke et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer
C Tecimer et al.
GYNECOLOGIC ONCOLOGY (2001)
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor
Q Zheng et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2000)
Urokinase receptor: a molecular organizer in cellular communication
KT Preissner et al.
CURRENT OPINION IN CELL BIOLOGY (2000)
Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma
K Inuzuka et al.
JOURNAL OF SURGICAL RESEARCH (2000)
Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism
R Ippoliti et al.
FASEB JOURNAL (2000)
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
L Zhou et al.
PATHOLOGY INTERNATIONAL (2000)
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma
T Itoh et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2000)
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma
H Shiomi et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
The urokinase plasminogen activator system as a novel target for tumour therapy
M Schmitt et al.
FIBRINOLYSIS & PROTEOLYSIS (2000)
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer
M Salden et al.
ANNALS OF ONCOLOGY (2000)
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study
M Thewes et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2000)
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer
C Tecimer et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2000)
分享论文
